Result of Retail Offer

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF VERICI DX PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS.

Capitalised terms used in this Announcement have the meaning given to them in the Retail Offer Launch Announcement (as defined below), unless otherwise defined in this Announcement.

Verici Dx plc

("Verici" or the "Company")

Result of Retail Offer

Further to the announcement made by the Company on 25 January 2024 (RNS number: 9314A) (the "Retail Offer Launch Announcement"), Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce that it has raised gross proceeds of £0.28 million pursuant to the Retail Offer which was oversubscribed. Overall, taking into account the £6.22 million raised via the Placing, the total gross proceeds of the Fundraising amount to £6.50 million. Subject to the Retail Offer becoming unconditional, a total of 3,111,111 new Ordinary Shares ("Retail Offer Shares") will be issued at 9.0 pence per Retail Offer Share ("Issue Price").

Consequently, and subject to the passing of certain resolutions (the "Resolutions"), which are required to implement the Fundraising, at the General Meeting, an application will be made to the London Stock Exchange for the admission of, in aggregate, 72,222,222 new Ordinary Shares (comprising 69,111,111 Placing Shares and 3,111,111 Retail Offer Shares) to trading on AIM. Admission and dealings in the new Ordinary Shares are expected to take place at 8.00 a.m. on 20 February 2024 ("Admission").

The Retail Offer is wholly conditional upon, inter alia, (i) the Resolutions being duly passed by the shareholders of the Company at the General Meeting to be held at 12 p.m. on 19 February 2024 at Shoosmiths LLP's office in London at No. 1 Bow Churchyard, London, EC4M 9DQ, (ii) admission of the Retail Offer Shares to trading on AIM and (iii) completion of the Placing and admission of the Placing Shares to trading on AIM.

Following Admission, the Company's enlarged issued ordinary share capital will be 242,541,467. This figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Information to Distributors

UK Product Governance Requirements